Psych CASC / OSCE · Psychopharmacology — metabolic syndrome and psychotropic monitoring
Explaining antipsychotic weight gain and a monitoring plan (CASC)
CASC-style station: explain metabolic risk in plain language, validate anger, negotiate monitoring and change options (lifestyle, switch, metformin) without abandoning relapse prevention.
On this page
Study tools
Target exams
Station instructions (candidate)
You have 7 minutes with the parents (and young person if present). Validate concern about weight and glucose, explain that some antipsychotics — including olanzapine — carry higher metabolic risk especially in young people, outline what monitoring should look like, and negotiate a plan: lifestyle support, possible switch to a lower-metabolic agent, possible metformin, and why abrupt stop of all treatment risks relapse. Avoid jargon without explanation. Do not promise zero risk. Do not dismiss their anger.[1][2][6]
References6ShowHide
- [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
- [2]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
- [3]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
- [4]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
- [5]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
- [6]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730